Aventis Pharma’s net profit has declined by 20.75% to Rs 40.1 crore for the first quarter ended March 31, 2012, over the same period previous year. The company reported a net profit of Rs 50.6 crore in the same period of previous year. The profit of the quarter has been impacted due to the amortisation costs relating to the brands and technical know how acquired in 2011 from Universal Medicare and lower interest income as a result of the above investment.
The pharmaceutical company’s net sales rose to Rs 322.5 crore for the first quarter ended March 31, 2012, as compared to Rs 276.3 crore in the corresponding period of last year.
The company's board has recommended a final dividend of Rs 29 per share of a face value of Rs 10 for the year ended December 31, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: